- Recommendation ID
- CG184/3
- Question
What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4):
-
to reduce severe oesophagitis
-
to control symptoms
-
as maintenance therapy?
-
- Any explanatory notes
(if applicable) People with severe erosive reflux disease or severe oesophagitis (Los Angeles classification grade C/D or Savary–Miller grade 3/4) experience severe heartburn, and prolonged acid and pepsin exposure in the lower oesophagus, which can affect their day-to-day wellbeing. It would substantially improve people's quality of life if an optimal treatment regimen could be identified. Currently, there is a lack of evidence on the efficacy of 'double-dose' PPIs in treating severe erosive reflux disease.
Source guidance details
- Comes from guidance
- Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- Number
- CG184
- Date issued
- September 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/10/2019 |